Proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) are one of the most maturely designed TPD tactics. With this review, we focus on both preclinical experiments and scientific trials to provide an extensive summary of the protection and scientific effectiveness of PROTACs and MGDs in hematologic malignancies in the last 20